MedTrace Logo

Study of Effects of Ticagrelor on Microparticles and Micro-RNA in NSTE-ACS

NCT02071966 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2016-07-26

No results posted yet for this study

Summary

The aim of the study is to learn more about the pathophysiology of acute coronary syndrome (ACS) and to evaluate the mechanisms responsible of the action and benefits of ticagrelor.

Ticagrelor is an oral and reversible inhibitor of P2Y12 receptor. Few information is available about the action of ticagrelor on the molecules involved in thrombogenesis and platelets activation in ACS.

The aim of this study is to evaluate the mechanisms of ticagrelor action in vivo.

It was observed that patients with myocardial infarction have higher blood levels of microparticles than patients with unstable angina or stable angina.

The investigators assumed that ticagrelor benefits are represented by a reduction of microparticle levels, a marker of endothelial dysfunction in patients with cardiovascular disease, and by a modification in microRNAs pattern, fragments of mRNA that have a regulatory action in various cellular processes (such as proliferation, differentiation, growth and cellular death) and represent new biomarkers in ACS.

Conditions

  • Non ST Segment Elevation Acute Coronary Syndrome

Interventions

DRUG

Ticagrelor

Comparison of Ticagrelor with another anti-platelet drug (Clopidogrel)

DRUG

Clopidogrel

Comparison of Clopidogrel with another anti-platelet drug (Ticagrelor)

Sponsors & Collaborators

  • Catholic University of the Sacred Heart

    lead OTHER

Principal Investigators

  • Luigi M Biasucci, Professor · Catholic University of the Sacred Heart

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2015-12-31
Completion
2016-11-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02071966 on ClinicalTrials.gov